|
Real-time Estimate
Cboe BZX
20:15:09 19/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 282.34 USD | -1.28% |
|
-4.04% | +23.66% |
| 03:46pm | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 12:49pm | AbbVie, Disco Pharmaceuticals Enter Solid Tumor Collaboration, Option-to-License Deal | MT |
| Market Cap | 506B 461B 426B 385B 725B 47,242B 753B 5,149B 2,035B 25,499B 1,897B 1,857B 80,520B | P/E 2026 * |
36.5x | P/E 2027 * | 26.8x |
|---|---|---|---|---|---|
| Enterprise Value | 569B 519B 480B 433B 815B 53,151B 847B 5,793B 2,290B 28,688B 2,134B 2,089B 90,590B | EV / Sales 2026 * |
8.39x | EV / Sales 2027 * | 7.56x |
| Free-Float |
95.64% | Yield 2026 * |
2.41% | Yield 2027 * | 2.54% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| ABBV | Delayed | |
| ABBV | Real-time | ||
| 4AB | Delayed | ||
| 4AB | Real-time | ||
| 4AB | Real-time | ||
| 0QCV | Delayed | ||
| ABBV * | End-of-day quote | ||
| 0QCV | Real-time | ||
| 4AB | Delayed | ||
| Real-time | |||
| 4AB | Delayed | ||
| 1ABBV | End-of-day quote | ||
| ABBV | Delayed | ||
| ABBV | End-of-day quote | ||
| ABBV | End-of-day quote | ||
| ABBVCL | End-of-day quote | ||
| ABBV | Delayed |
Last Transcript: AbbVie Inc.
| 1 day | -1.30% | ||
| 1 week | -4.24% | ||
| Current month | -4.38% | ||
| 1 month | -0.25% | ||
| 3 months | +6.02% | ||
| 6 months | +31.91% | ||
| Current year | +23.41% |
| 1 week | 279.88 | 301.2 | |
| 1 month | 278.01 | 302.93 | |
| Current year | 190.75 | 302.93 | |
| 1 year | 190.75 | 302.93 | |
| 3 years | 137.14 | 302.93 | |
| 5 years | 115.01 | 302.93 | |
| 10 years | 58.6 | 302.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 55 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 59 | 23/06/2022 |
Linda Ray
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 65 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 74 | 01/01/2013 |
Ed Rapp
BRD | Director/Board Member | 69 | 01/01/2013 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/30/26 A | Free | Director | 59 | 0.0000% | ||
| 9/30/26 A | Free | Director | 129 | 0.0000% | ||
| 8/14/26 A | Exercice | Executive/Senior Manager | 98,130 | 0.0056% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.27% | -4.24% | +21.07% | +103.87% | 506B | ||
| -2.05% | -4.88% | +29.35% | +127.18% | 1,232B | ||
| -2.08% | -5.87% | +31.78% | +78.02% | 656B | ||
| -1.04% | -1.80% | +28.69% | +68.33% | 382B | ||
| -2.87% | -8.59% | +41.32% | +30.81% | 340B | ||
| -3.22% | -5.20% | +24.48% | +50.97% | 294B | ||
| -2.51% | -4.49% | -2.15% | +31.64% | 278B | ||
| -0.93% | -5.57% | +28.81% | +66.22% | 240B | ||
| -1.23% | -0.48% | +30.51% | +119.93% | 210B | ||
| -2.32% | -3.84% | -14.65% | -62.29% | 176B | ||
| Average | -1.90% | -2.12% | +21.92% | +61.47% | 431B | |
| Weighted average by Cap. | -1.87% | -2.58% | +25.50% | +81.35% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 67.79B 61.83B 57.17B 51.59B 97.16B 6,335B 101B 690B 273B 3,419B 254B 249B 10,797B | 74.02B 67.51B 62.42B 56.33B 106B 6,917B 110B 754B 298B 3,734B 278B 272B 11,789B |
| Net income | 14.35B 13.09B 12.1B 10.92B 20.57B 1,341B 21.38B 146B 57.77B 724B 53.84B 52.71B 2,286B | 19.32B 17.62B 16.29B 14.7B 27.69B 1,805B 28.78B 197B 77.77B 974B 72.47B 70.96B 3,077B |
| Net Debt | 63.23B 57.66B 53.31B 48.11B 90.61B 5,908B 94.19B 644B 255B 3,189B 237B 232B 10,070B | 54.29B 49.51B 45.78B 41.31B 77.8B 5,073B 80.87B 553B 219B 2,738B 204B 199B 8,646B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/11/26 | $282.48 | -1.24% | 1,793,472 |
| 18/11/26 | $286.01 | -2.33% | 4,842,258 |
| 17/11/26 | $292.82 | -0.59% | 3,950,014 |
| 16/11/26 | $294.55 | -0.16% | 5,493,798 |
| 13/11/26 | $295.03 | +0.20% | 3,262,103 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
















